QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

MLYS

QT66Mineralys Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
24.63
-0.50-1.99%
OverviewShort InterestFilings
MLYSQT66Mineralys Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
24.63-1.99%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own35.24%
Shs Outstand88.12M
Perf Week2.88%
Market Cap1.67BForward P/E-EPS next Y-2.10Insider Trans0.64%Shs Float-Perf Month-5.38%
Enterprise Value1.55BPEG-EPS next Q-0.54Inst Own-Short Float-Perf Quarter5.80%
Income-121452485.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y-31.66%
Sales-P/B3.26EPS next Y9.25%ROA-23.25%Short Interest-Perf YTD-32.13%
Book/sh7.34P/C-EPS next 5Y-ROE-27.92%52W High47.65 -48.31%Perf Year78.74%
Cash/sh7.46P/FCF-EPS past 3/5Y-ROIC-26.87%52W Low12.59 95.63%Perf 3Y-
Dividend Est.-EV/EBITDA-10.24Sales past 3/5Y-Gross Margin0.00%Volatility3.13% 4.28%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM43.99%Oper. Margin0.00%ATR (14)1.57Perf 10Y-
Dividend Ex-Date-Quick Ratio44.33Sales Y/Y TTM-Profit Margin0.00%RSI (14)42.85Recom2.13
Dividend Gr. 3/5Y-Current Ratio44.33EPS Q/Q40.51%SMA20-7.50%Beta0.89Target Price46.00
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA50-10.75%Rel Volume2.67Prev Close25.13
Employees51LT Debt/Eq-EarningsAug 11SMA200-25.57%Avg Volume1.52MPrice24.63
IPO DateFeb 10, 2023Option/ShortYes / YesEPS/Sales Surpr.7.84% -Net Debt/EBITDA0.74Volume4,062,205Change-1.99%
Analyst Ratings
DateActionAnalystRatingTarget
Mar-13-26ReiteratedJefferiesHold$30
Mar-10-26ReiteratedH.C. Wainwright$52 → $56
Dec-19-25ReiteratedStifel Nicolaus$45 → $52
Oct-30-25ReiteratedH.C. Wainwright$42 → $52
May-14-25ReiteratedGuggenheimBuy$52 → $48
Apr-02-25ReiteratedH.C. Wainwright$30 → $42
Apr-02-24ReiteratedGoldman Sachs$30
Latest News
Jun-17-26
Jun-17-2610:58PM
Mineralys: Limited Differentiation Makes Lorundrostat A Weak CompetitorSeekingAlpha
01:35PM
7 Health Care Stocks With Whale Alerts In Today's SessionBenzinga
Jun-15-26
Jun-15-2603:01AM
Reported Sunday, Mineralys Therapeutics Presents Late-Breaking Data At ENDO 2026 Showing Lorundrostat Associated With Significant Reductions In Six Of Eleven Heart Failure Risk BiomarkersBenzinga
Jun-11-26
Jun-11-2603:22AM
Mineralys Therapeutics, Inc. (MLYS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeekingAlpha
03:22AM
Mineralys Therapeutics, Inc. (MLYS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit
000
Selling, General and Administrative Excl. Other392414
Research and Development13216970
Other Operating Expense0-11
Operating Income-171-192-85
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)-16-15-13
Net Income Before Taxes-155-178-72
Income Taxes
000
Consolidated Net Income-155-178-72
Net Income From Continuing Operations-155-178-72
Net Income-155-178-72
EPS (Recurring)-2.29-3.66-1.99
EPS (Basic, Before Extraordinaries)-2.29-3.66-1.99
EPS (Diluted)-2.29-3.66-1.99
EBITDA-155-178-72
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding684936
Market Capitalization2,468——
Operating Lease Expense
———
Insider Trading Volume
$25.33$23.81$22.28$20.75$19.23● Close Price0.00M15.02M30.03M45.05M60.07MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Karydas DaphneDirectorJun 17 '26Option Exercise12.026,00072,12038,000Jun 17 12:00 AM
Karydas DaphneDirectorJun 17 '26Sale25.003,00075,0006,200Jun 17 12:00 AM
Rodman David MalcomChief Medical OfficerJun 17 '26Option Exercise14.369,168131,63683,334Jun 17 12:00 AM
Rodman David MalcomChief Medical OfficerJun 17 '26Sale25.004,584114,60057,095Jun 17 12:00 AM
Rodman David MalcomChief Medical OfficerJun 15 '26Option Exercise10.207,08472,256113,334Jun 17 12:00 AM
Rodman David MalcomChief Medical OfficerJun 15 '26Sale23.819,890235,48757,095Jun 17 12:00 AM
Rodman David MalcomChief Medical OfficerJun 12 '26Option Exercise1.0812,69813,71469,792Jun 12 12:00 AM
Rodman David MalcomChief Medical OfficerJun 12 '26Sale23.936,349151,90163,443Jun 12 12:00 AM
Rodman David MalcomChief Medical OfficerJun 10 '26Option Exercise16.004,34069,44065,613Jun 12 12:00 AM
Rodman David MalcomChief Medical OfficerJun 10 '26Sale25.002,17054,25063,443Jun 12 12:00 AM
Rodman David MalcomChief Medical OfficerMay 18 '26Option Exercise15.4483412,87663,860May 19 12:00 AM
Rodman David MalcomChief Medical OfficerMay 18 '26Sale27.5541711,48863,443May 19 12:00 AM
Rodman David MalcomChief Medical OfficerMay 13 '26Option Exercise12.3915,414190,968116,876May 13 12:00 AM
Rodman David MalcomChief Medical OfficerMay 13 '26Sale28.5814,056401,78963,443May 13 12:00 AM
Rodman David MalcomChief Medical OfficerMay 12 '26Option Exercise1.0812,69613,71276,140May 13 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR